Medical/Pharmaceuticals

TenNor Therapeutics Reports Positive Phase IIa POC Data for Rifaquizinone (TNP-2092), the First Non-Surgical Therapy Candidate for Periprosthetic Joint Infection

— Phase IIb multicenter trial initiated, bringing this potential life-changing therapy closer to patients — SUZHOU, China, Sept. 10, 2026 /PRNewswire/ -- TenNor Therapeutics, a near-commercial-stage biotechnology company, today announced positive topline results from a Phase IIa proof-of-concept...

2026-09-10 19:30 2884

/C O R R E C T I O N -- CordenPharma/

In the news release, CordenPharma Boosts Aseptic Fill-Finish Capacity to 500 Million Sterile Injectable Units Per Year, issued 10-Sep-2026 by CordenPharma over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details ...

2026-09-10 19:28 3046

Novo Holdings invests in ForYou Medical to support global growth in advanced wound care manufacturing

SINGAPORE, Sept. 10, 2026 /PRNewswire/ -- Novo Holdings, a leading global healthcare and life sciences investor, today announced a strategic minority investment in Huizhou ForYou Medical Devices Co., Ltd. ("ForYou Medical"), a China-based contract development and manufacturing organisation (CDMO)...

2026-09-10 15:00 13825

BGI Genomics Launches "Digital Life Twin" Framework to Power Proactive Health

SHENZHEN, China, Sept. 9, 2026 /PRNewswire/ -- Commemorating BGI Group's 27th anniversary, BGI Genomics today introduced its Digital Life Twin framework alongside an advanced multi-omics diagnostic portfolio at the 2026 Global New Product Launch Event. Grounded in over two decades of population-s...

2026-09-09 21:45 3355

Yuyu Pharma CEO Robert Wonsang Yu Launches "Robert's YUniverse" Podcast

SEOUL, South Korea, Sept. 9, 2026 /PRNewswire/ -- Robert Wonsang Yu, CEO of Yuyu Pharma, has launched"Robert's YUniverse ", a new podcast series featuring conversations with guests from across culture, business and animal health....

2026-09-09 21:00 5066

First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA

BEIJING and BRIDGEWATER, Mass., Sept. 9, 2026 /PRNewswire/ -- Gan&Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan&Lee) announced that the first participant has been dosed in a First-In-Human (FIH) Phase 1 study of GZC8072 tablets, a novel ultra-long-acting oral peptide GLP-1 RA form...

2026-09-09 21:00 4975

Clinical Psychologist Urges Women to Recognise the Signs of a Dysregulated Nervous System

MELBOURNE, Australia, Sept. 9, 2026 /PRNewswire/ -- Women are becoming increasingly skilled at functioning while struggling, says Clinical Psychologist Dr Jennifer Menon, who is urging women to recognise signs of prolonged stress and trauma before reaching breaking point.

2026-09-09 20:56 2297

Moonwalk Biosciences Announces $70 Million Series B: NYSE Content Update

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Sept. 9, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begin...

2026-09-09 20:56 6860

Full-Life Technologies Announces U.S. FDA IND Clearance and Australian Regulatory Clearance for [²²⁵Ac]Ac-FL-261 Phase 1 Clinical Trial

LONDON, Sept. 9, 2026 /PRNewswire/ -- Full-Life Technologies ("Full-Life", the "Company"), a privately held, fully integrated, clinical-stage actinium-based global radiopharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the Company's Investigati...

2026-09-09 20:25 2966

Transcenta Therapeutics and WuXi Biologics Enter into Strategic Collaboration to Accelerate Commercialization of HiCB Continuous Bioprocessing Technologies

PRINCETON, N.J. and SUZHOU, China, Sept. 9, 2026 /PRNewswire/ -- Transcenta Therapeutics (HKEX: 06628), a global clinical-stage biopharmaceutical company with fully integrated capabilities in discovery, R&D and process development of antibody-based therapeutics, today announced that it and its su...

2026-09-09 20:00 2376

Daesang Targets Global Pharmaceutical Amino Acid Market, Building on 70 Years of Fermentation Technology

* Leverages fermentation know-how developed through MIWON to expand beyond general-purpose amino acids into high-value pharmaceutical materials * Acquires Germany-based AMINO GmbH, gaining purification technology, European regulatory expertise, and a global customer network SEOUL, South Kore...

2026-09-09 20:00 3978

Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved therapies currently exist SYDNEY, Sept. 9, 2026 /PRNewswire/ -- Kazia Therapeutics Limited

2026-09-09 19:30 2508

Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy

* Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning with MSS clinical stage II-III colon cancer * Phase 2 trial of porustobart for colon cancer will be open for enrollment early in the fourth q...

2026-09-09 19:12 2964

Abbott and Sengkang General Hospital expand partnership to advance early detection of muscle loss and support healthy aging

* The expanded three-year collaboration will integrate muscle health screenings into hospital and community settings, train healthcare professionals, and increase public education * Since launching in 2023, the partnership has trained nearly 300 healthcare professionals to assess muscle healt...

2026-09-09 18:10 2320

HanchorBio Reaches Clinical Milestone for HCB101 as US FDA Allows Continued Treatment for Phase 1 Patient Experiencing Clinical Benefit

HCB101 represents the first known U.S. Expanded Access case for a SIRPα Fc fusion protein enabling continued therapy beyond the parent study. TAIPEI and SHANGHAI and SAN FRANCISCO, Sept. 9, 2026 /PRNewswire/ -- HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developi...

2026-09-09 18:00 2099

Cleveland Clinic, RIKEN and IBM Team Advance to Finals for 2026 ACM Gordon Bell Prize

Joint research team modeled a 12,635-atom protein, the largest-known to be simulated using quantum computers. Breakthrough was achieved through quantum and classical methods working together, expanding quantum-centric supercomputing's potential in life sciences research. CLEVELAND and WAKO, Jap...

2026-09-09 12:00 2582

Lunit Unveils New AI-Powered Tumor Microenvironment Insights in Lung Cancer at WCLC 2026

Three studies explore the relationship between tumor microenvironment, genomic alterations, and treatment response in non-small cell lung cancer using AI-based analysis SEOUL, South Korea, Sept. 8, 2026 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and preci...

2026-09-08 21:00 3324

Metabolon Verus™ Metabolomics Profiling Kit Now Available to Order

A successful multi-site ring trial and early access program demonstrate the reproducibility, scalability, and biological insight of the Metabolon Verus™ Metabolomics Profiling Kit across laboratories worldwide MORRISVILLE, N.C., Sept. 8, 2026 /PRNewswire/ -- Metabolon, Inc., the global leader in...

2026-09-08 21:00 1932

Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo

NEW YORK and SUZHOU, China, Sept. 8, 2026 /PRNewswire/ -- Accro Bioscience (Suzhou) Limited ("Accro") today announced that Shanghai Fosun Pharmaceutical Industrial Development Company Limited ("Fosun Pharma Industrial"), a subsidiary of its partner Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ...

2026-09-08 20:20 2218

HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study

* The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with twice-yearly dosing. * HBM9378/WIN378 produc...

2026-09-08 20:17 2624
1 ... 24252627282930 ... 642